BOSTON, Mass., August 22, 2022 – Imbria Pharmaceuticals, Inc., a clinical stage, cardio-metabolic company developing novel therapies designed to enhance cellular energetics, today announced that data from IMPROVE-DiCE, Phase 2a, open-label trial, will be presented at the upcoming European Society of Cardiology (ESC) Congress, being held August 26-29, 2022 in Barcelona, Spain.

Date: Friday, August 26, 2022
Title: A Phase 2a Trial Investigating Ninerafaxstat – A Novel Cardiac Mitotrope for the treatment of Diabetic Cardiomyopathy (IMPROVE-DiCE)
Lead Author and Presenter: M. J. Hundertmark, Oxford Centre for Clinical Magnetic Resonance Research (OCMR), University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
ESC Session Title: CMR in the Evaluation of Cardiomyopathies and Heart Failure
Location: Station 1
Time: 14:15 to 15:00 CEST

About ninerafaxstat (formerly IMB-1018972)
Our lead product candidate, ninerafaxstat, is a novel, investigational cardiac mitotrope in development for a range of cardiac diseases characterized by a fundamental imbalance between energy consumption and energy supply in the heart resulting in cardiac energy deficiency. As a partial fatty acid oxidation (pFOX) inhibitor, ninerafaxstat is designed to shift cardiac substrate selection towards glucose oxidation which generates more energy in the form of adenosine triphosphate (ATP) per unit of oxygen consumed, increasing cardiac metabolic efficiency to support better cardiac function.